[Ip-health] Financial Times: Drugs groups diversify away from patents

Thiru Balasubramaniam thiru at keionline.org
Mon Oct 25 08:20:22 PDT 2010


http://www.ft.com/cms/s/0/d6fb3f60-dc9d-11df-84f5-00144feabdc0.html

Drugs groups diversify away from patents
By Andrew Jack in London

Published: October 21 2010 01:34 | Last updated: October 21 2010 01:34

Two-thirds of large pharmaceutical companies are focused on  
diversifying away from patented drug development as they grow  
increasingly sceptical about the returns from future innovation.

A survey by Roland Berger, the strategy consultancy, of 50 top  
industry executives showed that 65 per cent considered their sector  
was facing a “strategic crisis” and 67 per cent saw diversification as  
a potential solution.

Almost half believed that current investments in research and  
development would yield a negative return, although two-thirds  
believed future scientific advances could yield positive returns over  
the next decade.
The negative perceptions towards innovation reflect the view of the  
financial markets, which are giving higher valuations to more  
diversified companies. “The industry does not trust its own innovative  
capabilities. We are burning money,” said one industry executive  
Roland Berger interviewed.

The report also highlights a growing divergence between companies.

Sanofi-Aventis of France placed greatest emphasis on diversification  
from 2004-2009, boosting non-patented drug sales from 5 per cent to 12  
per cent.

Pfizer, Merck, Johnson & Johnson, Novartis and GlaxoSmithKline also  
moved in this direction. Groups facing a steep “cliff” of patents  
which expire in the coming years have generally moved furthest in  
diversifying in response, led by Sanofi-Aventis, which will soon lose  
exclusivity on its blockbuster Plavix.

Industry-wide, it estimates 57 per cent of 2008 sales will be off  
patent within three years and 75 per cent within five years.

But some companies with similar patent pressures, including Eli Lilly,  
have diversified far less, while Bristol-Myers Squibb has instead shed  
non-core activities to bet on enhanced innovation in its pipeline of  
experimental drugs.

A few other drug companies have also concentrated on pharmaceutical  
operations, led by Roche and – until recently – AstraZeneca, which  
since 2008 has also diversified a little and expressed some interest  
in generic drug sales.

The report stressed that there are significant variations in the  
approach taken to diversification, with the majority focused on de- 
risking through a shift into generics, consumer health and vaccines.  
While these tactics increase the scope to boost sales and expand into  
emerging markets, the report suggests greater value could come from  
diversification into more innovative areas, notably into personalised  
healthcare and diagnostics.

The report stresses the potential to increase efficacy and value in a  
way sought by healthcare systems and insurers – from integrating drugs  
with genetic markets, imaging and molecular markers, and with medical  
devices.

While integration into enhanced “healthcare value” could boost  
returns, Roland Berger concludes: “Most executives still shy away from  
this path due to the perceived magnitude of change required.”

One anonymous interviewee said the industry was a “victim of its own  
pipeline focus”.


------------------------------------------------------------


Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International (KEI)
thiru at keionline.org


Tel: +41 22 791 6727
Mobile: +41 76 508 0997








More information about the Ip-health mailing list